NCT03523442View on ClinicalTrials.gov

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2018

Primary Completion Date

July 9, 2019

Study Completion Date

December 31, 2026

Conditions
Prostatic Neoplasms
Interventions
DRUG

Apalutamide

The participants will receive apalutamide 240 mg once daily orally.

Trial Locations (4)

100083

Peking University Third Hospital, Beijing

100142

Beijing Cancer Hospital of Peking University, Beijing

200032

Fudan Cancer Hospital, Shanghai

210000

Jiangsu Cancer Hospital, Nanjing

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY